CRISPR Has Left the Lab—What Happens Next?
November 19, 2025 · 3 min read · by Bhavya Gupta
CRISPR used to sound like one of those technologies that belonged entirely in science-fiction movies. Edit DNA? Change genes? Sounds futuristic. Except it isn't really futuristic anymore.
CRISPR-based treatments are now reaching actual patients. In 2026, the FDA expanded approval of Casgevy, a CRISPR-based treatment for sickle-cell disease, to children as young as two. Another experimental CRISPR treatment has also shown that a single infusion could keep lowering cholesterol for at least a year. Suddenly, “editing DNA” doesn't sound quite so far away.
The basic idea is surprisingly simple: find a particular piece of DNA and change it. CRISPR acts a little like a biological editing tool, allowing scientists to target specific genetic instructions.
That opens up a very different way of thinking about medicine. Instead of treating a problem again and again, could we fix the underlying genetic cause?
But once CRISPR leaves the lab, things get complicated. Scientists have to worry about unintended edits, long-term effects, how to deliver the treatment to the right cells, and whether these therapies can become affordable enough for more than a tiny group of patients. The FDA is now developing specific safety guidance for genome-editing treatments, showing just how quickly this field is moving.
And then comes the slightly uncomfortable question: if we can eventually edit genes to prevent disease, what happens when people want to edit things that aren't diseases? Where do we draw the line?
That's where CRISPR stops being just a biology story and starts becoming a much bigger conversation about medicine, ethics and what we actually want to change about ourselves.
CRISPR isn't a magical “delete anything” button, and scientists still have plenty to figure out.
But one thing is for sure: gene editing has moved from something scientists experimented with in cells to something doctors can actually use in patients.
The next chapter isn't really about whether we can edit DNA.
“It’s about figuring out when we should.”